Circuit Rankings prioritizes neural circuits for therapeutic intervention and research focus in neurodegenerative disease. The ranking system integrates multiple factors including therapeutic accessibility, clinical impact, mechanistic understanding, and current research activity to guide both scientific investigation and clinical development priorities[@deveney2022].
Neural circuits represent the fundamental organizational units of brain function, and their targeted dysfunction underlies the characteristic symptom profiles of different neurodegenerative diseases. Understanding which circuits offer the greatest therapeutic potential—and which are most actively researched—helps prioritize resource allocation for drug discovery, device development, and clinical trial design.
This page ranks circuits across three dimensions: therapeutic targeting potential (how accessible and impactful intervention could be), research activity (publication volume and trial intensity), and disease burden (how directly each circuit relates to specific neurodegenerative conditions).
Neural circuits are prioritized for therapeutic intervention based on their accessibility to various modulation techniques, the feasibility of achieving clinically meaningful effects, and their direct contribution to disease symptoms[@chen2023].
Circuit Rankings prioritizes neural circuits for therapeutic intervention and research focus in neurodegenerative disease. The ranking system integrates multiple factors including therapeutic accessibility, clinical impact, mechanistic understanding, and current research activity to guide both scientific investigation and clinical development priorities[@deveney2022].
Neural circuits represent the fundamental organizational units of brain function, and their targeted dysfunction underlies the characteristic symptom profiles of different neurodegenerative diseases. Understanding which circuits offer the greatest therapeutic potential—and which are most actively researched—helps prioritize resource allocation for drug discovery, device development, and clinical trial design.
This page ranks circuits across three dimensions: therapeutic targeting potential (how accessible and impactful intervention could be), research activity (publication volume and trial intensity), and disease burden (how directly each circuit relates to specific neurodegenerative conditions).
Neural circuits are prioritized for therapeutic intervention based on their accessibility to various modulation techniques, the feasibility of achieving clinically meaningful effects, and their direct contribution to disease symptoms[@chen2023].
| Rank | Circuit | Target Potential | Primary Modulation Methods | Key Disease Applications |
|------|---------|-----------------|---------------------------|--------------------------|
| 1 | Basal Ganglia Motor Circuit | Very High | DBS, pharmacology, gene therapy | PD, Huntington's, DBS for dystonia |
| 2 | Default Mode Network | High | TMS, behavioral, pharmacological | AD, depression, cognitive enhancement |
| 3 | Cholinergic Basal Forebrain | High | Pharmacological, cell therapy | AD, cognitive decline |
| 4 | Locus Coeruleus Noradrenergic | Medium-High | Pharmacological, neuromodulation | AD, PD, arousal disorders |
| 5 | Serotonergic Raphe | Medium | Pharmacological | Depression, impulse control in neurodegeneration |
| Rank | Circuit | Target Potential | Primary Modulation Methods | Key Disease Applications |
|------|---------|-----------------|---------------------------|--------------------------|
| 6 | Motor Cortex | Moderate | TMS, cortical stimulation, rehabilitation | ALS, PD, stroke-related neurodegeneration |
| 7 | Cerebellar Circuit | Moderate | TMS, pharmacological, DBS (dentate nucleus) | MSA, PSP, ataxia disorders |
| 8 | Hippocampal Circuit | Moderate | Pharmacological, environmental enrichment, direct stimulation | AD, vascular dementia |
| 9 | Limbic Circuit (Amygdala-Hippocampus) | Moderate | Pharmacological, behavioral | AD, FTD emotional symptoms |
| 10 | Prefrontal Executive Circuit | Moderate | TMS, cognitive training, pharmacological | FTD, PD dementia, vascular cognitive impairment |
| Rank | Circuit | Target Potential | Primary Modulation Methods | Key Disease Applications |
|------|---------|-----------------|---------------------------|--------------------------|
| 11 | Thalamocortical Sensory Circuits | Low-Moderate | Targeted pharmacological, emerging DBS | PD sensory symptoms, pain circuits |
| 12 | Brainstem Respiratory Centers | Low | Pharmacological, adaptive servo-ventilation | MSA, ALS |
| 13 | Enteric Nervous System | Low | Microbiome-based, pharmacological | PD (gut-first hypothesis) |
| 14 | Microglial-Neuronal Immune Circuits | Low | Immunomodulatory, anti-inflammatory | AD, PD neuroinflammation |
| 15 | Oligodendrocyte Myelin Circuits | Low | Remyelination agents, trophic support | MS-related neurodegeneration, MSA |
Research activity reflects publication volume, clinical trial registration, and NIH funding allocation across 2024-2025, indicating which circuits are receiving the most scientific attention and investment[@marchetti2021].
| Rank | Circuit | Publications (2024-2025) | Clinical Trials Active | NIH Funding (approx.) |
|------|---------|--------------------------|----------------------|---------------------|
| 1 | Basal Ganglia Motor Circuit | 4,500+ | 80+ | Very High |
| 2 | Default Mode Network | 3,200+ | 45+ | High |
| 3 | Hippocampal Circuit | 2,800+ | 35+ | Very High |
| 4 | Motor Cortex Pathway | 2,100+ | 25+ | High |
| 5 | Prefrontal Executive Circuit | 1,800+ | 20+ | Moderate-High |
| 6 | Limbic System (Amygdala) | 1,400+ | 15+ | Moderate |
| 7 | Cerebellar Circuit | 1,200+ | 18+ | Moderate |
| 8 | Cholinergic Basal Forebrain | 950+ | 12+ | Moderate |
| 9 | Pain Circuit (Spinothalamic) | 880+ | 22+ | Moderate |
| 10 | Brainstem Arousal Circuit | 750+ | 8+ | Low-Moderate |
Rapidly Growing Circuits (>20% YoY growth):
| Priority | Circuit | Rationale | Therapeutic Target |
|----------|---------|-----------|-------------------|
| 1 | Default Mode Network | Central to memory consolidation, early amyloid deposition | Anti-amyloid, TMS, cognitive training |
| 2 | Hippocampal Circuit | Core memory system, early tau pathology | Tau-targeted therapies, neurotrophic factors |
| 3 | Locus Coeruleus | Earliest site of neurodegeneration, noradrenergic modulation | Neuroprotective agents, LC stimulation |
| 4 | Cholinergic Basal Forebrain | Postsynaptic cortical target for symptomatic treatment | Cholinesterase inhibitors, M1 agonists |
| 5 | Prefrontal Executive Circuit | Contributes to working memory and planning deficits | Cognitive enhancers, TMS |
| Priority | Circuit | Rationale | Therapeutic Target |
|----------|---------|-----------|-------------------|
| 1 | Basal Ganglia Motor Circuit | Direct substrate of dopaminergic loss | DBS (STN, GPi), dopaminergic agents, LRRK2 inhibitors |
| 2 | Enteric Nervous System | Gateway for alpha-synuclein propagation, non-motor symptoms | Microbiome intervention, GI-targeted therapies |
| 3 | Brainstem Arousal Circuit | Sleep disorders, rapid eye movement behavior disorder | REM sleep stabilization, neuroprotective |
| 4 | Pain Circuit | Common non-motor symptom, thalamic involvement | SNRIs, gabapentinoids, targeted analgesics |
| 5 | Limbic Circuit | Contributes to depression and impulse control disorders | Dopamine agonists, serotonergic agents |
| Disease | Priority Circuit | Rationale |
|---------|-----------------|-----------|
| PSP | Brainstem Oculomotor Circuit | Hallmark vertical gaze palsy, earliest diagnostic marker |
| PSP | Basal Ganglia Prefrontal Circuit | Executive dysfunction, postural instability |
| CBS | Thalamocortical Sensorimotor Circuit | Cortical-basal degeneration, apraxia, alien limb |
| CBS | Frontoparietal Attention Circuit | Asymmetric cortical involvement |
| MSA | Autonomic Brainstem Circuit | Cardiovascular dysregulation, key diagnostic feature |
| MSA | Cerebellar Circuit | Cerebellar ataxia in MSA-C subtype |
The [basal ganglia motor circuit](/circuits/parkinson-basal-ganglia-circuit) is the highest-priority therapeutic target in neurodegeneration, driven by its central role in Parkinson's disease and its accessibility to deep brain stimulation[@chen2023]. The circuit comprises the striatum (caudate and putamen), globus pallidus externus (GPe) and internus (GPi), subthalamic nucleus (STN), and substantia nigra pars reticulata (SNr) and compacta (SNc).
In PD, loss of dopaminergic input from the SNc disrupts the balance between the direct pathway (facilitating movement) and indirect pathway (suppressing competing movements). This results in excessive GPi/SNr output, which hyper-inhibits the thalamus, reducing excitatory drive to the motor cortex. The circuit is accessible through multiple modalities: dopaminergic medication (oral, transdermal, subcutaneous), DBS at STN or GPi, and lesioning procedures.
The default mode network (DMN) comprises the medial prefrontal cortex, posterior cingulate cortex, precuneus, angular gyrus, and hippocampal formation, active during rest and internally directed cognition[@marchetti2021]. In AD, amyloid deposition and tau pathology disrupt DMN connectivity, particularly in the precuneus and posterior cingulate, correlating with episodic memory deficits and disease progression.
The DMN is accessible through non-invasive techniques: repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex, cognitive training paradigms that engage DMN nodes, and pharmacological modulation of the glutamatergic and GABAergic systems within the network.
The cerebellar circuit participates in motor coordination, motor learning, and increasingly recognized cognitive functions[@singh2023]. The circuit includes the cerebellar cortex (Purkinje cells, granule cells, molecular layer interneurons), deep cerebellar nuclei (dentate, interposed, fastigial), and their projections to the ventrolateral thalamus and onward to motor and prefrontal cortex.
In neurodegeneration, the cerebellum is differentially affected: MSA-C shows primary cerebellar atrophy; PSP shows degeneration of dentate nucleus and cerebellarthalamic pathways; the cerebellar circuit contributes to gait and postural dysfunction in PD. Therapeutic targeting includes TMS of the cerebellum, transcranial direct current stimulation (tDCS), and experimental DBS of the dentate nucleus.
The prefrontal executive circuit comprises dorsolateral prefrontal cortex (DLPFC), ventrolateral PFC, anterior cingulate cortex (ACC), and their connections to the basal ganglia and hippocampus[@leonard2022]. This circuit underlies working memory, cognitive flexibility, planning, and inhibitory control—all functions compromised in frontotemporal dementia, PD dementia, and vascular cognitive impairment.
Non-invasive modulation through high-frequency rTMS of the DLPFC has shown promise for cognitive enhancement in AD and FTD. The circuit's distributed nature across both hemispheres allows bilateral stimulation strategies.
Thalamocortical circuits relay sensory information from specific thalamic nuclei to primary sensory and association cortices[@nguyen2024]. In neurodegeneration, these circuits are affected through thalamic pathology (PD pain syndrome, CBS thalamic involvement) and through cortical atrophy that disrupts thalamocortical feedback loops.
The ventral posterior nucleus and ventral lateral nucleus of the thalamus show early changes in several neurodegenerative conditions. Emerging therapeutic approaches include targeted pharmacological agents and experimental thalamic DBS for pain and motor dysfunction.
DBS is the gold standard for circuit modulation in movement disorders, with established targets for PD (STN, GPi), tremor (VIM thalamus), and dystonia (GPi). Emerging targets include:
TMS offers non-invasive circuit modulation with increasing evidence for:
Circuit-level pharmacology targets specific neurotransmitter systems:
Circuit dysfunction correlates with specific disease burden metrics[@wang2024]:
Rankings are derived from a composite scoring methodology incorporating:
Each factor contributes equally to the final composite score, normalized to a 0-100 scale. Research activity metrics use absolute publication counts; therapeutic potential uses expert panel consensus.
Circuit rankings guide clinical decision-making at multiple levels:
Drug Development: Prioritizing circuits with high therapeutic potential and existing target validation accelerates pipeline decisions. The basal ganglia circuit's ranking reflects decades of target validation, making it a lower-risk target compared to emerging circuits like the locus coeruleus.
Device Development: DBS target selection is informed by circuit rankings and clinical evidence. The STN and GPi rank highest based on extensive trial data; novel targets like the pedunculopontine nucleus are classified as Tier 2 pending larger trials.
Clinical Trial Design: Outcome measure selection aligns with circuit-level dysfunction. Trials targeting the DMN in AD select memory consolidation endpoints; basal ganglia-targeted trials use motor Unified Parkinson's Disease Rating Scale (UPDRS) measures.
Emerging technologies are reshaping circuit targeting priorities:
Closed-Loop DBS: Adaptive stimulation systems that respond to real-time neural activity markers (beta-band oscillations in PD, theta activity in AD) offer improved therapeutic windows and reduced side effects. The basal ganglia circuit is leading this development.
Chemogenetics (DREADDs): Engineered receptors allow circuit-specific pharmacological activation or inhibition. Currently preclinical, DREADDs may offer new targeting opportunities for circuits that are challenging for electrical or pharmacological approaches.
Focused Ultrasound: Non-invasive lesioning and neuromodulation through intact skull, with emerging targets in the thalamus for tremor and pain, and the locus coeruleus for AD.
Cell Replacement: Grafts of dopaminergic neurons ( embryonic stem cell-derived or iPSC-derived) target the basal ganglia circuit directly. Clinical trials are in early phases for PD.
Optogenetics: Light-based control of specific neuronal populations offers unprecedented precision but remains limited to experimental settings. Translation to human therapy will require viral delivery and safety validation.
The current rankings cover 15+ major circuits but many disease-specific circuits remain underscribed. Priority gaps for expansion include:
Individual circuit pages should be created or expanded for:
| Page | Status | Priority |
|------|--------|----------|
| [PSP Basal Ganglia Circuit](/circuits/psp-basal-ganglia-circuit) | Missing | High |
| [CBS Cortical Circuit](/circuits/cbs-cortical-circuit) | Missing | High |
| [MSA Cerebellar Circuit](/circuits/msa-cerebellar-circuit) | Missing | Medium |
| [Huntington's Disease Circuit](/circuits/huntingtons-circuit) | Missing | Medium |
| [DLB Limbic Circuit](/circuits/dlb-circuit) | Missing | Medium |
| [ALS Motor Circuit](/circuits/als-motor-circuit) | Missing | Medium |